15
Participants
Start Date
December 31, 2010
Primary Completion Date
March 31, 2014
Study Completion Date
March 31, 2014
Panitumumab
6 mg/kg, 60-90 minute IV infusion every 2 weeks
Oxaliplatin
85 mg/m2, 2-hour IV infusion every 2 weeks
Irinotecan
125 mg/m2, 1-hour IV infusion every 2 weeks
Leucovorin
200 mg/m2, 2-hour IV infusion every 2 weeks
5-Fluorouracil
3200 mg/m2 IV, 48-hour continuous infusion every two weeks
Center for Cancer and Blood Disorders, Bethesda
Northeast Georgia Medical Center, Gainesville
Florida Hospital Cancer Institute, Orlando
Florida Cancer Specialists, St. Petersburg
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Family Cancer Center, Collierville
Oncology Hematology Care, Inc, Cincinnati
Hope Cancer Center, Terre Haute
Providence Medical Group, Terre Haute
NEA Baptist Clinic, Jonesboro
The Center for Cancer and Blood Disorders, Fort Worth
Portsmouth Regional Hospital, Portsmouth
Hematology-Oncology Associates of Northern NJ, Morristown
Collaborators (1)
Amgen
INDUSTRY
SCRI Development Innovations, LLC
OTHER